Gilead to Buy Kite for Promising Cancer Therapies in $12 Billion Deal Gilead to Buy Kite for Promising Cancer Therapies in $12 Billion Deal

Gilead Sciences Inc agreed to buy Kite Pharma Inc in a nearly $12 billion deal on Monday, as it looks to replace flagging sales from hepatitis C drugs with an emerging and expensive class of cancer immunotherapies that are expected to generate billions of dollars in revenue.Reuters Health Information
Source: Medscape Today Headlines - Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Related Links:

To the Editor The multicenter study by Xu et al concluding that recurrence after hepatocellular carcinoma (HCC) resection is associated with sex deserves robust comment. The sophisticated multivariate Cox regression analyses failed to account for smoking status (dose and duration and also cessation after resection) despite smoking being an independent and a dose-related contributing factor for HCC all over the world, including Asia. The mean relative risk was 1.5 but exposure was high, specifically in China, where the prevalence of smoking was almost 50% in men, 22-fold that of women. In a large European cohort, the popula...
Source: JAMA Surgery - Category: Sports Medicine Source Type: research
By HANS DUVEFELT MD Jeanette Brown had lost twenty pounds, and she was worried. “I’m not trying,” she told me at her regular diabetes visit as I pored over her lab results. What I saw sent a chill down my spine: A normal weight, diet controlled diabetic for many years, her glycosylated hemoglobin had jumped from 6.9 to 9.3 in three months while losing that much weight. That is exactly what happened to my mother some years ago, before she was diagnosed with the pancreatic cancer that took her life in less than two years. Jeanette had a normal physical exam and all her bloodwork except for t...
Source: The Health Care Blog - Category: Consumer Health News Authors: Tags: Health Policy Medicare Hans Duvefelt Managed Care Source Type: blogs
Liver cancer (hepatocellular carcinoma [HCC]) incidence and mortality rates have been increasing in most countries for several decades. Currently, HCC is the second most common cause of cancer-related death in the world and represents the fastest rising cause of cancer-related deaths in the United States. Chronic hepatitis B virus (HBV) and hepatitis C virus are the primary underlying causes of HCC, with contributions from alcohol, tobacco, aflatoxin, obesity, and metabolic syndrome. In patients with chronic hepatitis C virus, the risk of HCC can be reduced rapidly with short-term, direct-acting antiviral medications. In c...
Source: JAMA Internal Medicine - Category: Internal Medicine Source Type: research
Liu et al. collected detailed information on liver cancer aetiology between 1990 –2016, derived from the global burden of disease in 2016. In this issue of the Journal, they show that liver cancer remains a major public health concern globally, though control of hepatitis B virus and hepatitis C virus infections has contributed to the decrease in liver cancer incidence in some regions. They report an unfavourable trend in countries with high socio-demographic index, including the Netherlands, the UK, and the USA.
Source: Journal of Hepatology - Category: Gastroenterology Authors: Tags: Editorial Desk Source Type: research
CONCLUSION: After establishing HCV replication, the lack of global changes in cellular gene expression indicates an adaptation to chronic infection, while the downregulation of mitochondrial respiratory chain genes indicates how a virus may further contribute to cancer cell-like metabolic reprogramming ("Warburg effect") even in the hepatocellular carcinoma cells used here. PMID: 30875926 [PubMed - in process]
Source: Molecular Medicine - Category: Molecular Biology Authors: Tags: Int J Mol Sci Source Type: research
AbstractChronic hepatitis B virus (HBV) and hepatitis C virus (HCV) infection are the most important underlying causes for the development of hepatocellular carcinoma (HCC) worldwide. Determining the optimal approach for management of the viral infection and the HCC depends on the virus and the stage of the cancer. In patients with HCV-associated HCC, there are multiple reasons to first treat the HCC. Firstly, in case of a curable HCC, the urgency for HCC treatment is important to avoid progression during HCV treatment. Secondly, the presence of HCC itself appears to reduce the rates of sustained virological response (SVR)...
Source: Digestive Diseases and Sciences - Category: Gastroenterology Source Type: research
This study provides evidence that the HCV core protein is a pro-metastatic protein that can interact directly with and modulate the functions of cellular metastasis suppressor Nm23-H1.
Source: Archives of Virology - Category: Virology Source Type: research
Fight Aging! provides a weekly digest of news and commentary for thousands of subscribers interested in the latest longevity science: progress towards the medical control of aging in order to prevent age-related frailty, suffering, and disease, as well as improvements in the present understanding of what works and what doesn't work when it comes to extending healthy life. Expect to see summaries of recent advances in medical research, news from the scientific community, advocacy and fundraising initiatives to help speed work on the repair and reversal of aging, links to online resources, and much more. This content is...
Source: Fight Aging! - Category: Research Authors: Tags: Newsletters Source Type: blogs
ConclusionsThere are no specific guideline recommendations regarding acute DVT treatment in long-term surveillance after liver transplantation. Low molecular weight heparin (LMWH), unfractionated heparin (UFH) and vitamin K antagonist (VKA) are the anticoagulants used in specific complications post-transplantation. The safety and the efficacy of direct anticoagulants in liver transplantation recipients need to be assessed in future trials. Given that long-term survival of liver transplantation is much improved, complications associated with transplantation and ageing require appropriate cardiovascular guidelines.
Source: Irish Journal of Medical Science - Category: General Medicine Source Type: research
A new study found that direct-acting antiviral treatment is linked to decreased risk of liver cancer, liver-related death, and all-cause mortality.  
Source: ConsultantLive - Category: Internal Medicine Authors: Tags: Hepatitis C Source Type: news
More News: Cancer | Cancer & Oncology | Cancer Therapy | Health | Hematology | Hepatitis | Hepatitis C | Immunotherapy | Pharmaceuticals